Next Article in Journal
Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus
Next Article in Special Issue
Comparison of Immunogenicity and Protective Efficacy of PPR Live Attenuated Vaccines (Nigeria 75/1 and Sungri 96) Administered by Intranasal and Subcutaneous Routes
Previous Article in Journal
Advanced Safety and Genetic Stability in Mice of a Novel DNA-Launched Venezuelan Equine Encephalitis Virus Vaccine with Rearranged Structural Genes
Open AccessArticle

Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs

The Pirbright Institute, Ash Road, Pirbright GU24 0NF, UK
Department of Medical-Veterinary Science, University of Parma, 43126 Parma, Italy
UnivLyon, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France
CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria 3219, Australia
Boehringer Ingelheim Animal Health, Bâtiment 700 R&D, 813 Cours du 3ème Millénaire, 69800 Saint Priest, France
Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, Queensland 4072, Australia
Authors to whom correspondence should be addressed.
These authors contributed equally.
Vaccines 2020, 8(1), 115;
Received: 10 February 2020 / Revised: 24 February 2020 / Accepted: 27 February 2020 / Published: 2 March 2020
Nipah virus (NiV) is an emergent pathogen capable of causing acute respiratory illness and fatal encephalitis in pigs and humans. A high fatality rate and broad host tropism makes NiV a serious public and animal health concern. There is therefore an urgent need for a NiV vaccines to protect animals and humans. In this study we investigated the immunogenicity of bovine herpesvirus (BoHV-4) vectors expressing either NiV attachment (G) or fusion (F) glycoproteins, BoHV-4-A-CMV-NiV-GΔTK or BoHV-4-A-CMV-NiV-FΔTK, respectively in pigs. The vaccines were benchmarked against a canarypox (ALVAC) vector expressing NiV G, previously demonstrated to induce protective immunity in pigs. Both BoHV-4 vectors induced robust antigen-specific antibody responses. BoHV-4-A-CMV-NiV-GΔTK stimulated NiV-neutralizing antibody titers comparable to ALVAC NiV G and greater than those induced by BoHV-4-A-CMV-NiV-FΔTK. In contrast, only BoHV-4-A-CMV-NiV-FΔTK immunized pigs had antibodies capable of significantly neutralizing NiV G and F-mediated cell fusion. All three vectored vaccines evoked antigen-specific CD4 and CD8 T cell responses, which were particularly strong in BoHV-4-A-CMV-NiV-GΔTK immunized pigs and to a lesser extent BoHV-4-A-CMV-NiV-FΔTK. These findings emphasize the potential of BoHV-4 vectors for inducing antibody and cell-mediated immunity in pigs and provide a solid basis for the further evaluation of these vectored NiV vaccine candidates. View Full-Text
Keywords: Nipah virus; bovine herpes virus 4; vaccine; pig; immunogenicity Nipah virus; bovine herpes virus 4; vaccine; pig; immunogenicity
Show Figures

Figure 1

MDPI and ACS Style

Pedrera, M.; Macchi, F.; McLean, R.K.; Franceschi, V.; Thakur, N.; Russo, L.; Medfai, L.; Todd, S.; Tchilian, E.Z.; Audonnet, J.-C.; Chappell, K.; Isaacs, A.; Watterson, D.; Young, P.R.; Marsh, G.A.; Bailey, D.; Graham, S.P.; Donofrio, G. Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs. Vaccines 2020, 8, 115.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop